JHPCY.US Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Healthcare Drug Manufacturers - Specialty & Generic USA Stocks
314.93 USD
Close of Nov 15, 2026
11.50 20.00
Market cap
USD 40.7B
P/E
31.4x
P/B
4.06x
ROE
13.8%
Dividend yield
0.48%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is JHPCY.US undervalued?

Graham number
Price314.93
Graham value132.29
Premium138.1%

JHPCY.US trades 138.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jiangsu Hengrui Pharmaceuticals Co.,Ltd fundamental analysis

No fundamental analysis for Jiangsu Hengrui Pharmaceuticals Co.,Ltd yet.

Jiangsu Hengrui Pharmaceuticals Co.,Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is …

Full company profile